Commenting on the acquisition, Venkat Krishnan, VP & Regional Director, Ranbaxy (North America), said: "The acquisition strengthens and extends the Ranbaxy franchise in the dermatology arena. It enables Ranbaxy to establish an immediate presence in high value segments, in addition to Acne, where we already have a dominant brand, Sotret
